Meaningful patient representation informing Canada’s cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review

Abstract

In this interview with the patient representatives on the Expert Review Committee (perc) of the Pan- Canadian Oncology Drug Review (pcodr), those representatives offer their views about how to be a valuable contributing member of Canada’s national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pcodr from the perspective of the patient representatives.